The increase in electronic drug delivery systems has led to both innovations and challenges. By uses an aerosolized approach to nicotine delivery, a “safer” alternative to traditional tobacco products was promised, but not necessarily delivered. Unfortunately, while arguably a less harmful drug delivery system, the jury is out as to the long terms effects of these systems. Of course, nicotine is not the only drug suitable for vape delivery. Cannabinoid products are now widely available; sometimes from reputable vendors, sometimes not. Participants in this presentation will gain an understanding of the technology behind “noncombusted” pulmonary drug delivery systems with a particular emphasis on nicotine (e-cigarettes) as well as cannabinoid products.